Nothing Special   »   [go: up one dir, main page]

PL378108A1 - Leczenie łączone do terapii zapalnych zaburzeń immunologicznych - Google Patents

Leczenie łączone do terapii zapalnych zaburzeń immunologicznych

Info

Publication number
PL378108A1
PL378108A1 PL378108A PL37810804A PL378108A1 PL 378108 A1 PL378108 A1 PL 378108A1 PL 378108 A PL378108 A PL 378108A PL 37810804 A PL37810804 A PL 37810804A PL 378108 A1 PL378108 A1 PL 378108A1
Authority
PL
Poland
Prior art keywords
treatment
combination therapy
immunoinflammatory disorders
immunoinflammatory
disorders
Prior art date
Application number
PL378108A
Other languages
English (en)
Inventor
Edward Roydon Jost-Price
Bradley B. Brasher
Todd W. Chappel
Palaniyandi Manivasakam
Noah Sachs
Brendan Smith
Benjamin A. Auspitz
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of PL378108A1 publication Critical patent/PL378108A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
PL378108A 2003-02-14 2004-02-12 Leczenie łączone do terapii zapalnych zaburzeń immunologicznych PL378108A1 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US44741503P 2003-02-14 2003-02-14
US44764803P 2003-02-14 2003-02-14
US44741203P 2003-02-14 2003-02-14
US44736603P 2003-02-14 2003-02-14
US44755303P 2003-02-14 2003-02-14
US46475303P 2003-04-23 2003-04-23
US50302603P 2003-09-15 2003-09-15

Publications (1)

Publication Number Publication Date
PL378108A1 true PL378108A1 (pl) 2006-03-06

Family

ID=32913413

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378108A PL378108A1 (pl) 2003-02-14 2004-02-12 Leczenie łączone do terapii zapalnych zaburzeń immunologicznych

Country Status (14)

Country Link
US (1) US20040224876A1 (pl)
EP (1) EP1599212A4 (pl)
JP (1) JP2006517969A (pl)
KR (1) KR20050110634A (pl)
AR (1) AR043188A1 (pl)
AU (1) AU2004212919A1 (pl)
CA (1) CA2514061A1 (pl)
HR (1) HRP20050804A2 (pl)
IS (1) IS8023A (pl)
MX (1) MXPA05008649A (pl)
NO (1) NO20053678L (pl)
PL (1) PL378108A1 (pl)
TW (2) TW200509958A (pl)
WO (1) WO2004073614A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812110D0 (en) 1998-06-06 1998-08-05 Levelrecall Limited Yttrium oxide based gas mantle
US6861056B2 (en) * 2001-06-05 2005-03-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
GB0307864D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1696894A1 (en) * 2003-12-01 2006-09-06 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ice inhibitors
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN101203214B (zh) * 2005-04-13 2012-11-21 艾升制药公司 用于治疗皮肤结缔组织疾病的β2-肾上腺素受体激动剂
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2007002120A2 (en) * 2005-06-23 2007-01-04 Duke University Fungicidal effect by regulating signal transduction pathways
ITMI20051826A1 (it) * 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
WO2007041677A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Soft tissue implants and drug combination compositions, and use thereof
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
RU2431845C2 (ru) * 2006-01-10 2011-10-20 Колгейт-Палмолив Компани Способы модулирования рецепторов клеточных поверхностей для предотвращения или снижения воспаления
AU2007211613C1 (en) * 2006-02-02 2018-01-04 Novartis Ag Tuberous Sclerosis treatment
AU2011205053B2 (en) * 2006-02-02 2013-02-07 Novartis Ag Tuberous Sclerosis treatment
US8207188B2 (en) * 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
EP2059234B1 (en) * 2006-09-08 2011-11-02 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
WO2008100539A1 (en) * 2007-02-12 2008-08-21 Michalis Nicolaou Treatment of copd, gastro-esophageal reflux disease (gerd), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, lra drugs, anti-h1 and/or anti-h2 drugs
EP2420236B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Terfenadine as anti-angiogenic agent
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
WO2009039246A2 (en) * 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
WO2010120275A2 (en) 2009-04-01 2010-10-21 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
AR076177A1 (es) 2009-04-01 2011-05-26 Colgate Palmolive Co MÉTODO PARA IDENTIFICAR UN COMPUESTO uTIL PARA TRATAR UNA ENFERMEDAD O CONDICIoN DE LA CAVIDAD ORAL
CA2753658C (en) 2009-04-01 2014-10-28 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
AR076041A1 (es) 2009-04-01 2011-05-11 Colgate Palmolive Co Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
KR101388235B1 (ko) * 2011-09-20 2014-04-24 가톨릭대학교 산학협력단 메클리진을 포함하는 관절염 예방 및 치료용 조성물
WO2017004454A1 (en) 2015-06-30 2017-01-05 Eiger Group International, Inc. Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
US10765630B2 (en) 2018-03-16 2020-09-08 SEN-JAM Pharmaceutical LLC Methods and compositions to treat enteropathic arthritis
KR102422449B1 (ko) * 2019-10-18 2022-07-20 연세대학교 산학협력단 결핵 및 비결핵항산균 감염 질환의 예방, 개선 또는 치료용 조성물
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101104A (en) * 1965-06-02 1968-01-31 Joseph Glasser Compositions for the treatment of psoriasis
US4444780A (en) * 1982-08-30 1984-04-24 Ortho Pharmaceutical Corporation Method for treating atopic dermatitis
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
AU710339B2 (en) * 1994-10-05 1999-09-16 Amarin Neuroscience Limited Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
FI104363B (fi) * 1997-05-19 2000-01-14 Timo Kalevi Korpela Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
CN1256085C (zh) * 1997-07-01 2006-05-17 美国辉瑞有限公司 舍曲林盐和舍曲林的缓释剂型
IN188720B (pl) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
EP1140087A4 (en) * 1998-12-18 2002-04-03 Du Pont Pharm Co N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
US20020006961A1 (en) * 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
CA2408889A1 (en) * 2000-05-08 2001-11-15 David Haines Immunosuppressive compositions
CA2424555A1 (en) * 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
JP2006503905A (ja) * 2002-09-24 2006-02-02 コンビナトアールエックス インコーポレーティッド 炎症性サイトカインのレベルの増大と関連する病気および障害の治療のための方法および試薬
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
KR20060076319A (ko) * 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 약물 조합들을 투여하는 치료 요법

Also Published As

Publication number Publication date
KR20050110634A (ko) 2005-11-23
CA2514061A1 (en) 2004-09-02
TW200509958A (en) 2005-03-16
AR043188A1 (es) 2005-07-20
NO20053678D0 (no) 2005-07-29
US20040224876A1 (en) 2004-11-11
JP2006517969A (ja) 2006-08-03
EP1599212A2 (en) 2005-11-30
EP1599212A4 (en) 2006-02-08
MXPA05008649A (es) 2005-11-23
NO20053678L (no) 2005-09-12
WO2004073614A3 (en) 2004-11-11
WO2004073614A2 (en) 2004-09-02
AU2004212919A1 (en) 2004-09-02
HRP20050804A2 (en) 2006-02-28
TW200902047A (en) 2009-01-16
IS8023A (is) 2005-09-13

Similar Documents

Publication Publication Date Title
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
EP1635813A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
IL164599A0 (en) Combination therapy for the treatment of cancer
AU2003286567A8 (en) Methods for the treatment of skin disorders
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
GB0316912D0 (en) Therapeutic treatment
GB0201850D0 (en) Therapeutic treatment
AU2003300791A1 (en) Combination therapy for the treatment of pain
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
IL173351A0 (en) Therapy of ocular disorders
GB0320806D0 (en) Therapeutic treatment
AU2003251875A8 (en) Combination therapy for the treatment of neoplasms
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
HRP20041159A2 (en) Combination for the treatment of airway disorders
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
GB0324283D0 (en) Therapeutic agents for the treatment of bone disorders
GB0317241D0 (en) Therapeutic agents for the treatment of bone disorders
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)